Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Upcoming Revised Foreign Investment Catalogue Will Continue To Promote Innovative Drug R&D

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State Council recently announced a plan to revise its Catalogue of Foreign Investment, which guides foreign investment and is, with this edition, opening more high-technology industries to foreign investment to encourage foreign companies to merge with and acquire Chinese firms engaged in high-tech industries

You may also be interested in...



China Releases New Policies To Welcome More Foreign Investment

SHANGHAI - China's State Council released April 13 new guidelines that allow more foreign investment in China that promise a better environment for overseas investment, drawing some relief for industry associations that consider recent policy moves as protectionist and that they say stifle cross-border innovation

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel